Literature DB >> 22753750

The organic arsenic derivative GMZ27 induces PML-RARα-independent apoptosis in myeloid leukemia cells.

Xiaodong Cheng1, Alfonso Quintás-Cardama, Mirna Golemovic, Ralph Zingaro, Ming-Zhang Gao, Emil J Freireich, Michael Andreeff, Hagop M Kantarjian, Srdan Verstovsek.   

Abstract

Arsenic trioxide (ATO) is an inorganic arsenic derivative that is very effective against acute promyelocytic leukemia. However, organic arsenic derivatives (OAD) have a more favorable toxicity profile than ATO. We herein characterized dipropil-S-glycerol arsenic (GMZ27), a novel OAD. GMZ27 had potent antiproliferative activity against human acute myeloid leukemia (AML) cell lines that was higher than that of ATO. In contrast to ATO, GMZ27 only marginally induced maturation of leukemia cells and had no effect on the cell cycle. The anti-leukemia activity of GMZ27 against AML cells was independent of the presence of the PML-RARα fusion protein. GMZ27 dissipates mitochondrial transmembrane potential, and induces cleavage of caspase 9 and activation of caspase 3 without altering the expression levels of (BCL-2), BAX and BCL-xl. GMZ27 induces the formation of intracellular superoxide, a reactive oxygen species (ROS) which plays a major role in the antileukemia activity of this OAD. In addition to ROS generation, GMZ27 concomitantly reduces intracellular glutathione which markedly weakens the cellular antioxidant capacity, thus enhancing the detrimental intracellular effects of ROS production. These results indicate that GMZ27 induces apoptosis in AML cells in a PML-RARα-independent fashion, through the induction of ROS production. This activity provides the rationale for the testing of GMZ27 in patients with AML.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22753750      PMCID: PMC5166574     

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  20 in total

1.  United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia.

Authors:  S L Soignet; S R Frankel; D Douer; M S Tallman; H Kantarjian; E Calleja; R M Stone; M Kalaycio; D A Scheinberg; P Steinherz; E L Sievers; S Coutré; S Dahlberg; R Ellison; R P Warrell
Journal:  J Clin Oncol       Date:  2001-09-15       Impact factor: 44.544

2.  Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not differentiation inducers in leukemia and lymphoma cells.

Authors:  Guo-Qiang Chen; Li Zhou; Miroslav Styblo; Felecia Walton; Yongkui Jing; Rona Weinberg; Zhu Chen; Samuel Waxman
Journal:  Cancer Res       Date:  2003-04-15       Impact factor: 12.701

Review 3.  Acute promyelocytic leukaemia: novel insights into the mechanisms of cure.

Authors:  Hugues de Thé; Zhu Chen
Journal:  Nat Rev Cancer       Date:  2010-10-22       Impact factor: 60.716

4.  PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3.

Authors:  Marion Jeanne; Valérie Lallemand-Breitenbach; Omar Ferhi; Marcel Koken; Morgane Le Bras; Stéphanie Duffort; Laurent Peres; Caroline Berthier; Hassane Soilihi; Brian Raught; Hugues de Thé
Journal:  Cancer Cell       Date:  2010-07-13       Impact factor: 31.743

5.  Arsenic trioxide induces apoptosis in peripheral blood T lymphocyte subsets by inducing oxidative stress: a role of Bcl-2.

Authors:  Sudhir Gupta; Leman Yel; Daniel Kim; Choong Kim; Sujata Chiplunkar; Sastry Gollapudi
Journal:  Mol Cancer Ther       Date:  2003-08       Impact factor: 6.261

6.  PML, a growth suppressor disrupted in acute promyelocytic leukemia.

Authors:  Z M Mu; K V Chin; J H Liu; G Lozano; K S Chang
Journal:  Mol Cell Biol       Date:  1994-10       Impact factor: 4.272

Review 7.  Arsenic and arsenic compounds.

Authors: 
Journal:  IARC Monogr Eval Carcinog Risk Chem Hum       Date:  1980

8.  Chemotherapy studies in an animal tumor spectrum. II. Sensitivity of tumors to fourteen antitumor chemicals.

Authors:  G S Tarnowski; F A Schmid; J G Cappuccino; C C Stock
Journal:  Cancer Res       Date:  1966-03       Impact factor: 12.701

9.  Bcl-2 antisense oligodeoxynucleotide increases the sensitivity of leukemic cells to arsenic trioxide.

Authors:  Y Zhang; W L Shen
Journal:  Cell Biol Int       Date:  2003       Impact factor: 3.612

Review 10.  Antioxidants, oxidative damage and oxygen deprivation stress: a review.

Authors:  Olga Blokhina; Eija Virolainen; Kurt V Fagerstedt
Journal:  Ann Bot       Date:  2003-01       Impact factor: 4.357

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.